{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T00:19:06Z","timestamp":1783124346280,"version":"3.54.6"},"reference-count":36,"publisher":"MDPI AG","issue":"17","license":[{"start":{"date-parts":[[2024,9,4]],"date-time":"2024-09-04T00:00:00Z","timestamp":1725408000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background\/Objectives: Psoriasis (PsO) is a chronic inflammatory skin disease that severely impacts patients\u2019 quality of life (QoL). Its global prevalence is about 2%, with significant regional variations. PsO manifests in the form of erythematous and scaly plaques, causing intense pruritus and discomfort and limiting daily activities. The condition often includes comorbidities such as psoriatic arthritis, cardiovascular diseases, and metabolic syndrome, further deteriorating QoL. Psychological well-being is notably affected, with high levels of depression and anxiety due to the visible lesions, leading to social stigma and isolation. QoL indexes like WHO-QoL and SF-36 assess various well-being aspects, while patient-reported outcomes (PROs) provide a comprehensive understanding of PsO\u2019s impact. However, there are no universally shared PROs in outpatient practice to fully understand the impact of the disease and associated therapies. This study aims to evaluate differences between DLQI and WHO-5 in adult patients with moderate-to-severe PsO treated with tildrakizumab 100 mg or 200 mg. Methods: The study was conducted at the University Hospital of Siena, Italy, from May 2023 to April 2024. Data from 15 patients treated with tildrakizumab 200 mg and 15 patients treated with tildrakizumab 100 mg, observed for at least 28 weeks, were recorded. Demographic data, PASI, DLQI, and WHO-5 scores were analyzed. Patients in the 100 mg group (G100) were selected to match the demographic characteristics of the 200 mg group (G200). Reduction rates of DLQI and WHO-5 were assessed at baseline values and after 4, 16, and 28 weeks. Results: Both groups experienced improvements in QoL. The group treated with 200 mg showed more pronounced and rapid reductions in DLQI and WHO-5 scores compared to the 100 mg group. WHO-5 demonstrated faster improvements in overall well-being than DLQI, indicating its greater sensitivity to changes in mental well-being and overall QoL. No differences in adverse events were observed between the two groups, with no major adverse events reported. Conclusions: In our study, WHO-5 proved more sensitive than DLQI in capturing well-being changes in PsO patients treated with tildrakizumab. However, a combined use of both WHO-5 and DLQI questionnaires should be encouraged in clinical practice. Furthermore, this study confirmed the superior QoL improvement associated with tildrakizumab 200 mg compared to 100 mg. Future research should explore the long-term impact on QoL and comparative effectiveness among other biologic therapies in diverse patient populations.<\/jats:p>","DOI":"10.3390\/jcm13175240","type":"journal-article","created":{"date-parts":[[2024,9,4]],"date-time":"2024-09-04T08:46:22Z","timestamp":1725439582000},"page":"5240","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Uncovering the Differences: How DLQI and WHO-5 Scores Vary in Moderate-to-Severe Psoriasis Patients Treated with Tildrakizumab 100 mg vs. 200 mg?"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8301-9206","authenticated-orcid":false,"given":"Emanuele","family":"Trovato","sequence":"first","affiliation":[{"name":"Dermatology Unit, Department of Medical, Surgical and Neurological Sciences, University of Siena, 53100 Siena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-9441-3923","authenticated-orcid":false,"given":"Martina","family":"Dragotto","sequence":"additional","affiliation":[{"name":"Dermatology Unit, Department of Medical, Surgical and Neurological Sciences, University of Siena, 53100 Siena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-1693-4539","authenticated-orcid":false,"given":"Eugenio","family":"Capalbo","sequence":"additional","affiliation":[{"name":"Dermatology Unit, Department of Medical, Surgical and Neurological Sciences, University of Siena, 53100 Siena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1818-6275","authenticated-orcid":false,"given":"Alessandra","family":"Cartocci","sequence":"additional","affiliation":[{"name":"Dermatology Unit, Department of Medical, Surgical and Neurological Sciences, University of Siena, 53100 Siena, Italy"},{"name":"Department of Medical Biotechnology, University of Siena, 53100 Siena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pietro","family":"Rubegni","sequence":"additional","affiliation":[{"name":"Dermatology Unit, Department of Medical, Surgical and Neurological Sciences, University of Siena, 53100 Siena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5238-2336","authenticated-orcid":false,"given":"Laura","family":"Calabrese","sequence":"additional","affiliation":[{"name":"Dermatology Unit, Department of Medical, Surgical and Neurological Sciences, University of Siena, 53100 Siena, Italy"},{"name":"Dermatologia, Dipartimento di Medicina e Chirurgia Traslazionale, Universit\u00e0 Cattolica del Sacro Cuore, 00168 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,9,4]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Bu, J., Ding, R., Zhou, L., Chen, X., and Shen, E. (2022). Epidemiology of Psoriasis and Comorbid Diseases: A Narrative Review. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.880201"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/978-3-030-92616-8_4","article-title":"The Immunogenetics of Psoriasis","volume":"1367","author":"Trovato","year":"2022","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1001\/jama.2020.4006","article-title":"Pathophysiology, Clinical Presentation, and Treatment of Psoriasis: A Review","volume":"323","author":"Armstrong","year":"2020","journal-title":"JAMA"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"249","DOI":"10.23736\/S2784-8671.23.07605-3","article-title":"Pso-Reg: A web registry for psoriasis in real life","volume":"158","author":"Trovato","year":"2023","journal-title":"Ital. J. Dermatol. Venereol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1007\/s13280-018-1090-3","article-title":"A review of quality of life (QOL) assessments and indicators: Towards a \u201cQOL-Climate\u201d assessment framework","volume":"48","author":"Estoque","year":"2019","journal-title":"AMBIO"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1159\/000353263","article-title":"Psychological Well-Being Revisited: Advances in the Science and Practice of Eudaimonia","volume":"83","author":"Ryff","year":"2014","journal-title":"Psychother. Psychosom."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"25","DOI":"10.2147\/PTT.S328447","article-title":"Assessing and Improving Psychological Well-Being in Psoriasis: Considerations for the Clinician","volume":"12","author":"Blackstone","year":"2022","journal-title":"Psoriasis Targets Ther."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"S26","DOI":"10.1016\/j.injury.2022.01.047","article-title":"Clinical practice guidelines: The good, the bad, and the ugly","volume":"54","author":"Madden","year":"2023","journal-title":"Injury"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1159\/000528945","article-title":"Patient Perspectives on Psoriatic Disease Burden: Results from the Global Psoriasis and Beyond Survey","volume":"239","author":"Armstrong","year":"2023","journal-title":"Dermatology"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1111\/jdv.12106","article-title":"Psoriasis Area Severity Index (PASI) and the Dermatology Life Quality Index (DLQI): The correlation between disease severity and psychological burden in patients treated with biological therapies","volume":"28","author":"Mattei","year":"2014","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"64","DOI":"10.5152\/eurjrheum.2019.19126","article-title":"Psoriasis Symptom Inventory (PSI) as a patient-reported outcome in mild psoriasis: Real life data from a large psoriatic arthritis registry","volume":"7","author":"Aydin","year":"2020","journal-title":"Eur. J. Rheumatol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1159\/000376585","article-title":"The WHO-5 Well-Being Index: A systematic review of the literature","volume":"84","author":"Topp","year":"2015","journal-title":"Psychother. Psychosom."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/s13555-022-00846-3","article-title":"Elevating the Standard of Care for Patients with Psoriasis: \u2018Calls to Action\u2019 from Epicensus, a Multistakeholder Pan-European Initiative","volume":"13","author":"Koren","year":"2023","journal-title":"Dermatol. Ther."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1080\/14712598.2022.1988566","article-title":"Tildrakizumab for treatment of moderate to severe psoriasis: An expert opinion of efficacy, safety, and use in special populations","volume":"22","author":"Galluzzo","year":"2022","journal-title":"Expert. Opin. Biol. Ther."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/S0140-6736(17)31279-5","article-title":"Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSUR-FACE 1 and reSURFACE 2): Results from two randomised controlled, phase 3 trials","volume":"390","author":"Reich","year":"2017","journal-title":"Lancet"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2350760","DOI":"10.1080\/09546634.2024.2350760","article-title":"Comparative effectiveness of tildrakizumab 200 mg versus tildrakizumab 100 mg in psoriatic patients with high disease burden or above 90 kg of body weight: A 16-week multicenter retrospective study\u2014IL PSO (Italian landscape psoriasis)","volume":"35","author":"Gargiulo","year":"2024","journal-title":"J. Dermatol. Treat."},{"key":"ref_17","first-page":"e15488","article-title":"Tildrakizumab in moderate-to-severe plaque psoriasis: A multicenter, retrospective, real-life study","volume":"35","author":"Caldarola","year":"2022","journal-title":"Dermatol. Ther."},{"key":"ref_18","first-page":"434","article-title":"Psoriasis and its management in women of childbearing age: Tools to increase awareness in dermatologists and patients","volume":"155","author":"Force","year":"2020","journal-title":"Ital. J. Dermatol. Venereol."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Zhang, H., Yang, Z., Tang, K., Sun, Q., and Jin, H. (2021). Stigmatization in Patients with Psoriasis: A Mini Review. Front. Immunol., 12.","DOI":"10.3389\/fimmu.2021.715839"},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Jankowiak, B., Krajewska-Ku\u0142ak, E., Jakoniuk, M., and Khvorik, D.F. (2023). Stigmatization among Patients with Plaque Psoriasis. J. Clin. Med., 12.","DOI":"10.3390\/jcm12196425"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1177\/08404704221110734","article-title":"Ageing, technology, and health: Advancing the concepts of autonomy and in-dependence","volume":"35","author":"Liu","year":"2022","journal-title":"Health Manag. Forum"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1007\/s00403-012-1235-3","article-title":"Social support and adaptation to the disease in men and women with psoriasis","volume":"304","author":"Janowski","year":"2012","journal-title":"Arch. Dermatol. Res."},{"key":"ref_23","first-page":"140","article-title":"World Health Organization Quality-of-Life Scale (WHOQOL-BREF): Analyses of Their Item Response Theory Properties Based on the Graded Responses Model","volume":"5","author":"Vahedi","year":"2010","journal-title":"Iran. J. Psychiatry"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1097\/00005650-199206000-00002","article-title":"The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection","volume":"30","author":"Ware","year":"1992","journal-title":"Med. Care"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1111\/j.1365-2133.2011.10469.x","article-title":"Patient-reported outcomes in psoriasis research and practice","volume":"165","author":"Otuki","year":"2011","journal-title":"Br. J. Dermatol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1080\/13543784.2023.2184684","article-title":"Investigational systemic drugs for moderate to severe plaque psoriasis: What\u2019s new?","volume":"32","author":"Calabrese","year":"2023","journal-title":"Expert Opin. Investig. Drugs"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/j.1365-2230.1994.tb01167.x","article-title":"Dermatology Life Quality Index(DLQI)\u2014A simple practical measure for routine clinical use","volume":"19","author":"Finlay","year":"1994","journal-title":"Clin. Exp. Dermatol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"adv20329","DOI":"10.2340\/actadv.v104.20329","article-title":"Correlation between Dermatology Life Quality Index and Psoriasis Area and Severity Index in Patients with Psoriasis: A Cross-sectional Global Healthcare Study on Psoriasis","volume":"104","author":"Maul","year":"2024","journal-title":"Acta Derm.-Venereol."},{"key":"ref_29","first-page":"2058","article-title":"The WHO-5 Well-Being Index: A Validation Study in People with Infertility","volume":"48","author":"Maroufizadeh","year":"2019","journal-title":"Iran. J. Public. Health"},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Campione, E., Lambiase, S., Shumak, R.G., Galluzzo, M., Lanna, C., Costanza, G., Borselli, C., Artosi, F., Cosio, T., and Tofani, L. (2023). A Real-Life Study on the Use of Tildrakizumab in Psoriatic Patients. Pharmaceuticals, 16.","DOI":"10.3390\/ph16040526"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1159\/000250839","article-title":"Severe psoriasis--oral therapy with a new retinoid","volume":"157","author":"Fredriksson","year":"1978","journal-title":"Dermatologica"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1111\/jdv.15862","article-title":"Tildrakizumab efficacy and impact on quality of life up to 52 weeks in patients with moderate-to-severe psoriasis: A pooled analysis of two randomized controlled trials","volume":"33","author":"Blauvelt","year":"2019","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1111\/bjd.18484","article-title":"Efficacy and safety of tildrakizumab for plaque psoriasis with continuous dosing, treatment interruption, dose adjustments and switching from etanercept: Results from phase III studies","volume":"182","author":"Kimball","year":"2020","journal-title":"Br. J. Dermatol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1111\/bjd.13932","article-title":"Tildrakizumab (MK-3222), an anti-interleukin-23p19 monoclonal antibody, improves psoriasis in a phase IIb randomized placebo-controlled trial","volume":"173","author":"Papp","year":"2015","journal-title":"Br. J. Dermatol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1159\/000496923","article-title":"The Evolution of Quality of Life Assessment and Use in Dermatology","volume":"235","author":"Chernyshov","year":"2019","journal-title":"Dermatology"},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Ghazawi, F.M., Mahmood, F., Kircik, L., Poulin, Y., Bourcier, M., Vender, R., Wiseman, M.C., Lynde, C., and Litvinov, I.V. (2021). A Review of the Efficacy and Safety for Biologic Agents Targeting IL-23 in Treating Psoriasis with the Focus on Tildrakizumab. Front. Med., 8.","DOI":"10.3389\/fmed.2021.702776"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/13\/17\/5240\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T15:48:32Z","timestamp":1760111312000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/13\/17\/5240"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,4]]},"references-count":36,"journal-issue":{"issue":"17","published-online":{"date-parts":[[2024,9]]}},"alternative-id":["jcm13175240"],"URL":"https:\/\/doi.org\/10.3390\/jcm13175240","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,4]]}}}